• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Interpersonal Values of Patients Participating in Phase II –III Clinical Trials: Implications for Clinical Trial Representativeness
ConclusionsThis novel analysis of the interpersonal values of patients that participate in Phase II and III clinical trials revealed that the patients ’ interpersonal values largely differed from those of the Portuguese normative population. Better understanding the implications of these findings for clinical trial representativeness and outcomes is of crucial importance.
Source: Pharmaceutical Medicine - May 30, 2023 Category: Drugs & Pharmacology Source Type: research

Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma
ConclusionFor patients with mediastinal lymphoma excess mortality risks from CVD and second cancers remain clinically significant despite contemporary chemotherapy and photon-RT. Efforts to reduce the toxicity of combined modality treatment, for example, using DIBH, reduced margins and advanced RT, e.g. proton beam therapy, should be continued to further reduce potentially fatal treatment effects.
Source: Clinical and Translational Oncology - April 23, 2023 Category: Cancer & Oncology Source Type: research

Pharmacological interventions for preventing atrial fibrillation after lung surgery: systematic review and meta-analysis
ConclusionCurrent clinical evidence supports the effectiveness of pharmacological intervention with beta-blockers, amiodarone, magnesium sulfate, or calcium-channel blockers to reduce the incidence of POAF after lung surgery in patients with lung cancer. In the absence of contraindications, prophylaxis with beta-blockers seems to be the most effective of the treatments studied.
Source: European Journal of Clinical Pharmacology - October 12, 2022 Category: Drugs & Pharmacology Source Type: research

The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations
CONCLUSIONS: Among Asians, immune checkpoint inhibitors were associated with an increased risk of major adverse cardiovascular events, particularly ischemic stroke and pulmonary embolism.PMID:36208180 | DOI:10.1093/jjco/hyac150
Source: Clinical Lung Cancer - October 8, 2022 Category: Cancer & Oncology Authors: Cho-Han Chiang Cho-Hung Chiang Kevin Sheng-Kai Ma Yuan Ping Hsia Yu-Wen Lee Han-Ru Wu Cho-Hsien Chiang Chun-Yu Peng James Cheng-Chung Wei Her-Shyong Shiah Cheng-Ming Peng Tomas G Neilan Source Type: research

Pharmacological interventions for preventing atrial fibrillation after lung surgery: systematic review and meta-analysis
CONCLUSION: Current clinical evidence supports the effectiveness of pharmacological intervention with beta-blockers, amiodarone, magnesium sulfate, or calcium-channel blockers to reduce the incidence of POAF after lung surgery in patients with lung cancer. In the absence of contraindications, prophylaxis with beta-blockers seems to be the most effective of the treatments studied.PMID:36136141 | DOI:10.1007/s00228-022-03383-2
Source: Clinical Lung Cancer - September 22, 2022 Category: Cancer & Oncology Authors: Xiaomei Wang Demei Zhang Yanxia Ren Jingjing Han Guangling Li Xueya Guo Source Type: research

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

CDKN2B-AS1: An indispensable long non-coding RNA in multiple diseases.
CONCLUSIONS: Long non-coding RNA CDKN2B-AS1 likely serves as a promising therapeutic target or prognosis biomarker in multiple human diseases. PMID: 32767927 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - August 4, 2020 Category: Drugs & Pharmacology Authors: Song C, Qi Y, Zhang J, Guo C, Yuan C Tags: Curr Pharm Des Source Type: research

Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients.
This study aimed to generate real-world evidence to assess the burden of comorbidities in COPD patients, to effectively manage these patients and optimize the associated healthcare resource allocation. ARCTIC is a large, real-world, retrospective cohort study conducted in Swedish COPD patients using electronic medical record data collected between 2000 and 2014. These patients were studied for prevalence of various comorbidities and for association of these comorbidities with exacerbations, mortality, and healthcare costs compared with an age-, sex-, and comorbidities-matched non-COPD reference population. A total of 17,47...
Source: Primary Care - September 10, 2018 Category: Primary Care Authors: Ställberg B, Janson C, Larsson K, Johansson G, Kostikas K, Gruenberger JB, Gutzwiller FS, Jorgensen L, Uhde M, Lisspers K Tags: NPJ Prim Care Respir Med Source Type: research

Preventable Heart Problems Killed 415,000 People in 2016. Here ’s How to Keep Your Heart Healthy
Heart problems that were “largely preventable” killed around 415,000 Americans in 2016, new data from the Centers for Disease Control and Prevention (CDC) says, highlighting the importance of proactive interventions. Under its new Million Hearts campaign, which aims to prevent a million heart attacks and strokes by 2022, the CDC looked at 2016 data and identified approximately 2.2 million hospitalizations and 415,000 deaths caused by heart attacks, strokes, heart failure and related conditions that likely could have been avoided. The total number of deaths related to heart issues is even higher — in 2015,...
Source: TIME: Health - September 6, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthytime Heart Disease onetime Source Type: news

Pages: 1  2